Boyce PM, Hackett LP, Ilett KF. Duloxetine transfer across the placenta during pregnancy and into milk during lactation. Arch Womens Ment Health 2011;14:169-72. [PubMed: 21359876] 6. Collin-Lévesque L, El-Ghaddaf Y, Genest M, et al. Infant exposure to methylphenidate and duloxetine during...
AM Thomson,DC West,PM Headley - 《European Journal of Neuroscience》 被引量: 179发表: 2010年 The role of neurokinin and N-methyl-D-aspartate receptors in synaptic transmission from capsaicin-sensitive primary afferents in the rat spinal cord in vitro. The rat spinal cord with connected dorsal ...
Duloxetine is most commonly administered in a capsule form due to good absorption via the oral route, and administration can be with or without food. Duloxetine should not be crushed or chewed. However, studies have shown that duloxetine may remain stable up to 2 hours after being opened and ...
to have a very small particle size, e.g. from 300 pm or lower; or to be and/or remain essentially free of agglomerates; or to be less or not very hygroscopic; or to help in formulating controlled release or immediate release formulations; or ...
21. Fendrick AM, Greenberg BP. A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild- to-moderate osteoarthritis. Osteopath Med Prim Care. 2009;3:1. 22. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in ...
31. Davidson JR, Wittchen HU, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double- blind placebo-controlled trial. European Neuropsychopharmacology. 2008;18:673–681. 32. Russell JM, Weisberg R, Fava M, Hartford JT, Erickson JS...
31. Davidson JR, Wittchen HU, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double- blind placebo-controlled trial. European Neuropsychopharmacology. 2008;18:673–681. 32. Russell JM, Weisberg R, Fava M, Hartford JT, Erickson JS...
21. Fendrick AM, Greenberg BP. A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild- to-moderate osteoarthritis. Osteopath Med Prim Care. 2009;3:1. 22. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in ...